


(R)-MG-132

Cat. No.:	HY-13259C	
CAS No.:	1211877-36-9	
Molecular Formula:	C ₂₆ H ₄₁ N ₃ O ₅	
Molecular Weight:	475.62	
Target:	Proteasome	
Pathway:	Metabolic Enzyme/Protease	
Storage:	Powder	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (210.25 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		2.1025 mL	10.5126 mL	21.0252 mL
		5 mM		0.4205 mL	2.1025 mL	4.2050 mL
10 mM		0.2103 mL	1.0513 mL	2.1025 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (5.26 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.83 mg/mL (1.75 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	(R)-MG-132 ((S,R,S)-(-)-MG-132) is the enantiomer of MG-132. (R)-MG-132 is a proteasome inhibitor with weaker cell cytotoxicity than MG-132. (R)-MG-132 stereoisomer is a more potent proteasome inhibitor than MG-132 ^[1] .
IC ₅₀ & Target	Proteasome ^[1]
In Vitro	(R)-MG-132, the stereoisomer of MG-132, is studied as a potential inhibitor of chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide hydrolyzing activities of proteasome ^[1] . MG-132 and (R)-MG-132 are investigated for inhibition of ChTL, trypsin-like (TL) and peptidylglutamyl peptide hydrolyzing

(PGPH) activities of purified 20S proteasomes isolated from human erythrocytes. For MG-132, the IC₅₀s of 0.89 μM, 104.43 μM, and 5.7 μM for ChTL, TL, and PGPH, respectively. For (R)-MG-132, the IC₅₀s of 0.22 μM, 34.4 μM, and 2.95 μM for ChTL, TL, and PGPH, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Struct Mol Biol. 2020 Oct;27(10):875-885.
- Cell, Molecular & Developmental Biology. 2020 Oct.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Mroczkiewicz M, et al. Studies of the synthesis of all stereoisomers of MG-132 proteasome inhibitors in the tumor targeting approach. J Med Chem. 2010 Feb 25;53(4):1509-18.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA